Basis: Trailing twelve months (TTM net income over the latest quarterly balance sheet). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the return on assets (ROA) high or low?
The return on assets (ROA) of 8.55% is 117% above its 5-year average of -51.23%, near the high end of its 5-year range (-82.69%–8.55%).
113.17% above its 12-month average of -64.90%.
Reported quarterly return on assets; no daily interpolation. Q2 FY2026 (2026-06-30): -0.05%.
RETURN ON ASSETS (ROA)
8.55%
RETURN ON ASSETS (ROA) AVG TTM
-64.90%
RETURN ON ASSETS (ROA) AVG 3Y
-64.30%
RETURN ON ASSETS (ROA) AVG 5Y
-51.23%
RETURN ON ASSETS (ROA) AVG 10Y
-24.79%
RETURN ON ASSETS (ROA) AVG 15Y
-4.73%
RETURN ON ASSETS (ROA) AVG 20Y
2.55%
CURRENT VS TTM AVG
+113.17%
CURRENT VS 3Y AVG
+113.30%
CURRENT VS 5Y AVG
+116.69%
CURRENT VS 10Y AVG
+134.49%
CURRENT VS 15Y AVG
+280.64%
CURRENT VS 20Y AVG
+235.21%
SECTOR MEDIAN · HEALTHCARE
-30.73%
median of 726 covered companies
CURRENT VS SECTOR MEDIAN
+127.83%
vs the sector median at left
Caris Life Sciences, Inc.
Market Cap
$8.01B
Return on Assets (ROA)
8.55%
TTM Avg
-64.90%
3Y Avg
-64.30%
5Y Avg
-51.23%
Market Cap
$7.77B
Return on Assets (ROA)
-24.40%
TTM Avg
-35.09%
3Y Avg
-99.06%
5Y Avg
-78.95%
Market Cap
$7.71B
Return on Assets (ROA)
-46.45%
TTM Avg
-48.58%
3Y Avg
-49.83%
5Y Avg
-41.46%
Market Cap
$7.65B
Return on Assets (ROA)
7.23%
TTM Avg
4.54%
3Y Avg
2.50%
5Y Avg
1.48%
Market Cap
$8.39B
Return on Assets (ROA)
4.91%
TTM Avg
-3.24%
3Y Avg
-6.85%
5Y Avg
-10.42%
Market Cap
$7.54B
Return on Assets (ROA)
13.18%
TTM Avg
-36.35%
3Y Avg
-30.02%
5Y Avg
-30.02%
Market Cap
$8.66B
Return on Assets (ROA)
-18.21%
TTM Avg
-20.38%
3Y Avg
-22.99%
5Y Avg
-19.64%
Market Cap
$7.36B
Return on Assets (ROA)
-18.86%
TTM Avg
-12.96%
3Y Avg
-12.20%
5Y Avg
-11.41%
Market Cap
$8.79B
Return on Assets (ROA)
-15.15%
TTM Avg
-26.36%
3Y Avg
-26.24%
5Y Avg
-23.50%
| NAME | MARKET CAP | RETURN ON ASSETS (ROA) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Caris Life Sciences, Inc. (CAI) | $8.01B | 8.55% | -64.90% | -64.30% | -51.23% |
| Praxis Precision Medicines, Inc. (PRAX)vs › | $7.77B | -24.40% | -35.09% | -99.06% | -78.95% |
| Cytokinetics, Incorporated (CYTK)vs › | $7.71B | -46.45% | -48.58% | -49.83% | -41.46% |
| HealthEquity, Inc. (HQY)vs › | $7.65B | 7.23% | 4.54% | 2.50% | 1.48% |
| Oscar Health, Inc. (OSCR)vs › | $8.39B | 4.91% | -3.24% | -6.85% | -10.42% |
| Hinge Health, Inc. (HNGE)vs › | $7.54B | 13.18% | -36.35% | -30.02% | -30.02% |
| Kymera Therapeutics, Inc. (KYMR)vs › | $8.66B | -18.21% | -20.38% | -22.99% | -19.64% |
| Ionis Pharmaceuticals, Inc. (IONS)vs › | $7.36B | -18.86% | -12.96% | -12.20% | -11.41% |
| Arrowhead Pharmaceuticals, Inc. (ARWR)vs › | $8.79B | -15.15% | -26.36% | -26.24% | -23.50% |
| Protagonist Therapeutics, Inc. (PTGX)vs › | $8.92B | 9.36% | 8.76% | -13.98% | -18.74% |
ROA
8.6%
ROE
17.8%
ROA = Net Income / Total Assets
Return on assets measures how efficiently a company generates profit from its total assets.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON ASSETS (ROA) |
|---|---|
| 2025-12-31 | -47.79% |
| 2024-12-31 | -82.01% |
| 2023-12-31 | -82.69% |
| 2022-12-31 | -44.72% |
| 2020-12-31 | 1.06% |
| 2019-12-31 | 1.07% |
| 2018-12-31 | 2.61% |
| 2017-12-31 | 2.96% |
| 2016-12-31 | 0.29% |
| 2015-12-31 | 1.35% |
| 2014-12-31 | 3.36% |
| 2013-12-31 | 3.82% |
| 2012-12-31 | 4.57% |
| 2011-12-31 | 5.26% |
| 2010-12-31 | 4.63% |
| 2009-12-31 | 3.62% |
| 2008-12-31 | -6.53% |
| 2007-12-31 | 5.36% |
| 2006-12-31 | 1.85% |
| 2005-12-31 | 5.53% |
| 2004-12-31 | 5.07% |
| 2003-12-31 | -1.37% |
